Aurobindo Pharma Receives USFDA Final Approval For Perampanel Tablets, Market Size Estimated At ₹558 Crore
Mumbai: Aurobindo Pharma announced on October 3, 2026, that it has received final approval from the USFDA to manufacture and market Perampanel Tablets in 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths. These tablets are bioequivalent and therapeutically equivalent to Fycompa® Tablets from Catalyst Pharmaceuticals, Inc. Market Opportunity The estimated market size for Perampanel Tablets stood…
Mumbai witnessed a significant development on October 3, 2026, as Aurobindo Pharma secured final approval from the USFDA to produce and sell Perampanel Tablets. Available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg, these tablets are bioequivalent and therapeutically comparable to Fycompa® Tablets from Catalyst Pharmaceuticals, Inc.
The estimated market potential for Perampanel Tablets reached US$ 67 million, or approximately ₹558 crore, for the twelve months leading up to August 2026, according to IQVIA MAT data. This achievement marks Aurobindo Pharma's current total of 599 ANDA (Approved New Drug Applications) approvals from the USFDA.
The production of Perampanel Tablets will take place at APL Healthcare, a wholly-owned subsidiary of Aurobindo Pharma, specifically at Unit-IV. The company anticipates launching the product in the third quarter of fiscal year 2027. Perampanel Tablets are primarily used for treating partial-onset seizures, including those that may be secondarily generalized, in patients aged 4 years and above.
Additionally, they are approved as an adjunctive treatment for primary generalized tonic-clonic seizures in patients aged 12 years and older.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Other reports of this story
- Aurobindo Pharma Gets USFDA Nod For Generic Epilepsy Tablets freepressjournal.in